Merz Therapeutics Presents New Research at World Parkinson Congress 2026, Revealing the Hidden Burden of "OFF" Episodes in Parkinson’s Disease

Contributed by: Business Wire

Logo

Tags

Research

FDA

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

Merz Therapeutics GmbH

More Like This

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao

PR Newswire associated0

NeuroDerm Announces Publication of Positive Results from Phase 3 BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations

Business Wire associated0

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Bial Launches KYNMOBI® (Apomorphine Hydrochloride) in the United Kingdom

Bial Launches Education and Awareness Campaign for World Parkinson’s Day

Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026

ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease